JPM vs URGN · P/E 14, rev $57.35B vs rev $109.8M
JPMorgan Chase & Co (JPM) versus UroGen Pharma Ltd (URGN) — a side-by-side from cached financials, not a winner call.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by James Dimon.
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Latest reported URGN revenue for 2025-12-31 was $109.8M. Net income was -$153.5M. URGN currently screens at market cap $1.61B.
JPM currently screens at market cap $805.69B and trailing P/E 14.2. URGN currently screens at market cap $1.61B.
Not investment advice. Open the JPM and URGN stock pages for the full models.
Not investment advice.